Oncolytic HSV-1 for the treatment of brain tumours.
The prognosis for patients diagnosed with malignant glioma, the most common primary tumour of the central nervous system, remains poor despite decades of research and advances in surgery, radiation and chemotherapy. The development of new approaches for the treatment of these tumours has led to the emergence of oncolytic viral therapy, with the use of conditionally replicating viruses, as a potential new intervention. Herpes simplex virus type 1 has emerged as the leading candidate oncolytic virus, with six different trials either completed or underway for patients with malignant glioma. In this review, the background of this approach will be discussed, followed by a discussion of the clinical trials, as well as potential directions for future trials.
Markert
James M
JM
Division of Neurosurgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35294-3410, USA. markert@uab.edu
Parker
Jacqueline N
JN
Buchsbaum
Donald J
DJ
Grizzle
William E
WE
Gillespie
G Yancey
GY
Whitley
Richard J
RJ
D001932:Brain Neoplasms / Q000628:therapy*; D002986:Clinical Trials as Topic; D015316:Genetic Therapy; D005822:Genetic Vectors; D005910:Glioma / Q000628:therapy*; D018259:Herpesvirus 1, Human / Q000235:genetics*; D006801:Humans; D050130:Oncolytic Virotherapy / Q000379:methods*